-
Diagnostic Value of KL-6 in ILD
KL-6 may be a useful biomarker in patients with interstitial lung disease, but there is limited information in non-Asian populations. Therefore, it is necessary to carry out studies in other populations to confirm the diagnostic values of the biomarker and its prognostic implication. Hypothesis KL-6 may be a useful biomarker in the management of interstitial lung diseases. But it is necessary to know more about its utility in the European population. Study Objectives: - To determine the concentration of KL-6 in serum of patients with pulmonary fibrosis at the time of diagnosis compared to patients without pulmonary...
18 Years and OverLearn More -
Diagnostic Value of Transbronchial Lung Cryobiopsy
Evaluating the diagnostic value of transbronchial lung cryobiopsy (TBLC) as well as its procedural feasibility and safety in a prospective series of 20 patients with diffuse interstitial lung diseases (DILD) who are referred for invasive histopathological diagnostics
18 Years - 75 YearsLearn More -
Diastolic Dysfunction and Interstitial Lung Edema in Septic Patients
Sepsis is one of the most challenging conditions with an exceptionally high mortality rate. Diastolic Dysfunction is common in septic patients and has been found to be associated with mortality. However, the reasons for this remain unclear. Therefore, the goal of this study is to investigate diastolic dysfunction in septic patients on the intensive care unit. Special attention is paid to the presence of lung edema and general edema as a potential link between diastolic dysfunction and elevated mortality in septic patients. During the septic phase daily ultrasound examinations of heart and lung will be performed as to monitor diastolic ...
30 Years and OverLearn More -
Digital Auscultation Test - IPF Data Collection
The aim of this study is the data collection for patients with IPF and symptom matched controls to create a database of lung auscultation sounds and basic patient characteristics.
45 Years and OverLearn More -
Dorothy P. and Richard P. Simmons Center for ILD Research Registry
The purpose of this study is to place past, current, and future medical record information into the UPMC Simmons Center for Interstitial Lung Disease Research Registry.
18 Years and OverLearn More -
Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection
The purpose of this study is to support the selection of a safe and tolerable tobramycin inhalation powder (TIP) dose, and regimen that exhibits effective bacterial reduction of P. aeruginosa in non-cystic fibrosis bronchiectasis (BE) patients with P. aeruginosa colonization.
18 Years and OverLearn More -
Early Diagnosis of Pulmonary Fibrosis - Diagnostic Delay
Patients with newly diagnosed IPF are investigated for the diagnostic delay before a diagnosis of IPF is made.
18 Years and OverLearn More -
Early Diagnosis of Pulmonary Fibrosis - Use of Biomarkers in Idiopathic Pulmonary Fibrosis
All incident cases of idiopathic pulmonary fibrosis (IPF) in Denmark will be offered inclusion during a 2 year period and followed up for at least 1 year with measurements of serum biomarkers and measurements of disease progression.
18 Years and OverLearn More -
Effects of Oxymizer Pendant Cannula Versus Conventional Nasal Cannula During Endurance Shuttle Walk Tests in Hypoxemic Patients With Idiopathic Pulmonary Fibrosis
Aim of this study is to investigate the effects of an Oxymizer pendant nasal cannula in hypoxemic patients with idiopathic pulmonary fibrosis during walking.
N/A and OverLearn More -
Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis
For pulmonary sarcoidosis, the initial dose recommended by the joint statement of the American Thoracic Society (ATS), European Respiratory Society (ERS), and The World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) is 20-40 mg per day.5 The exact dose and duration of treatment for sarcoidosis are unknown.4 We hypothesize that a higher dose of 40 mg per day as compared to a 20 mg/day dose of prednisone will be more effective in preventing post-treatment relapse by effective initial suppression of the granulomatous inflammation and reduction of the disease load. In this study, we compare the efficacy and safety of...
18 Years - 65 YearsLearn More
translate
